Related references
Note: Only part of the references are listed.GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein
Clemens R. Scherzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases
Katrin Beyer et al.
NEUROGENETICS (2008)
α-Synuclein and Parkinson disease susceptibility
S. Winkler et al.
NEUROLOGY (2007)
Interactions between metals and α-synuclein -: function or artefact?
David R. Brown
FEBS JOURNAL (2007)
Parkinson's disease: Genetics and beyond
N. N. Inamdar et al.
CURRENT NEUROPHARMACOLOGY (2007)
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice
Debomoy K. Lahiri et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The 5 '-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element
A. L. Friedlich et al.
MOLECULAR PSYCHIATRY (2007)
Identification of a risk haplotype of the α-synuclein gene in Japanese with sporadic Parkinson's disease
Hideaki Kobayashi et al.
MOVEMENT DISORDERS (2006)
α-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis
Kristin E. Larsen et al.
JOURNAL OF NEUROSCIENCE (2006)
Different modes and potencies of translational repression by sequence-specific RNA-protein interaction at the 5′-UTR
Minghua Nie et al.
NUCLEIC ACIDS RESEARCH (2006)
Mechanisms of Parkinson's disease linked to pathological α-synuclein:: New targets for drug discovery
Virginia M. -Y. Lee et al.
NEURON (2006)
α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models
Antony A. Cooper et al.
SCIENCE (2006)
Diagnosis and treatment of Parkinson disease: molecules to medicine
Joseph M. Savitt et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
Omar M. A. El-Agnaf et al.
FASEB JOURNAL (2006)
Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients
Ornit Chiba-Falek et al.
MOVEMENT DISORDERS (2006)
alpha-synuclein fission yeast model - Concentration-dependent aggregation without plasma membrane localization or toxicity
KA Brandis et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2006)
alpha-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers
Katrin Beyer
ACTA NEUROPATHOLOGICA (2006)
Agrin binds α-synuclein and modulates α-synuclein fibrillation
IH Liu et al.
GLYCOBIOLOGY (2005)
α-synuclein cooperates with CSPα in preventing neurodegeneration
S Chandra et al.
CELL (2005)
α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy
KE Paleologou et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2005)
Eukaryotic translation initiation factor 4GI and p97 promote cellular internal ribosome entry sequence-driven translation
P Hundsdoerfer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Nosology of Parkinson's disease: Looking for the way out of a quackmire
MS Forman et al.
NEURON (2005)
Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation
ME Bordeleau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Forcing nonamyloidogenic β-synuclein to fibrillate
G Yamin et al.
BIOCHEMISTRY (2005)
Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat plus maneb-induced Parkinson disease phenotype
M Thiruchelvam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
α-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells
WW Smith et al.
JOURNAL OF NEUROSCIENCE (2005)
Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway
R Cappai et al.
FASEB JOURNAL (2005)
α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease
L Chen et al.
NATURE NEUROSCIENCE (2005)
Pathogenic effects of α-synuclein aggregation
D Lundvig et al.
MOLECULAR BRAIN RESEARCH (2005)
The role of α-synuclein in neurodegenerative diseases
MC Bennett
PHARMACOLOGY & THERAPEUTICS (2005)
P25α stimulates a-synuclein aggregation and is co-localized with aggregated α-synuclein in α-synucleinopathies
E Lindersson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
α-synuclein and Parkinson's Disease
A Recchia et al.
FASEB JOURNAL (2004)
Proteasomal inhibition by α-synuclein filaments and oligomers
E Lindersson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Role of protein-water interactions and electrostatics in α-synuclein fibril formation
LA Munishkina et al.
BIOCHEMISTRY (2004)
Tissue trans glutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease
G Andringa et al.
FASEB JOURNAL (2004)
The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia
JJ Zarranz et al.
ANNALS OF NEUROLOGY (2004)
Differential expression of α-synuclein isoforms in dementia with Lewy bodies
K Beyer et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2004)
Does cellular iron dysregulation play a causative role in Parkinson's disease?
D Kaur et al.
AGEING RESEARCH REVIEWS (2004)
Functional consequences of α-synuclein tyrosine nitration -: Diminished binding to lipid vesicles and increased fibril formation
R Hodara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Hsp70 reduces α-synuclein aggregation and toxicity
J Klucken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation
PT Kotzbauer et al.
EXPERIMENTAL NEUROLOGY (2004)
Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9:: resemblance to pathogenetic changes in Parkinson's disease
M Yamada et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Synucleins and their relationship to Parkinson's disease
O von Bohlen und Halbach
CELL AND TISSUE RESEARCH (2004)
α-Synuclein regulation of the dopaminergic transporter:: a possible role in the pathogenesis of Parkinson's disease
A Sidhu et al.
FEBS LETTERS (2004)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease
CR Scherzer et al.
HUMAN MOLECULAR GENETICS (2003)
Modulation of dopamine transporter function by α-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress
C Wersinger et al.
FASEB JOURNAL (2003)
α-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma
OMA El-Agnaf et al.
FASEB JOURNAL (2003)
Certain metals trigger fibrillation of methionine-oxidized α-synuclein
G Yamin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Ubiquitination of α-synuclein is not required for formation of pathological inclusions in α-synucleinopathies
DM Sampathu et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Part II:: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
KK Dev et al.
NEUROPHARMACOLOGY (2003)
A structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins
R Bussell et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Accumulation of phosphorylated α-synuclein in aging human brain
Y Saito et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment
BM Ravina et al.
NEUROLOGY (2003)
Polycation-induced oligomerization and accelerated fibrillation of human α-synuclein in vitro
J Goers et al.
PROTEIN SCIENCE (2003)
Iron-activated iron uptake:: A positive feedback loop mediated by iron regulatory protein 1
MT Núñez et al.
BIOMETALS (2003)
The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease
R Sharon et al.
NEURON (2003)
Tissue transglutaminase-induced aggregation of α-synuclein:: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies
E Junn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis
S Krishnan et al.
BIOCHEMISTRY (2003)
Drug discovery targeted to the Alzheimer's APP mRNA 5 '-untranslated region - The action of paroxetine and dimercaptopropanol
S Payton et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2003)
Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion
N Gosavi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript
JT Rogers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Structural and functional implications of C-terminal regions of α-synuclein
TD Kim et al.
BIOCHEMISTRY (2002)
α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway
JH Seo et al.
FASEB JOURNAL (2002)
TorsinA and heat shock proteins act as molecular chaperones:: suppression of α-synuclein aggregation
PJ McLean et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Neuroferritinopathy: A window on the role of iron in neurodegeneration
DE Crompton et al.
BLOOD CELLS MOLECULES AND DISEASES (2002)
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
W Dauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
D Kaur et al.
AGING CELL (2002)
Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease
BA Faucheux et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes
TT Ding et al.
BIOCHEMISTRY (2002)
α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease
C Lo Bianco et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Alzheimer's disease drug discovery targeted to the APP mRNA 5′untranslated region
JT Rogers et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2002)
Structure/function of α-synuclein in health and disease:: rational development of animal models for Parkinson's and related diseases
PJ Kahle et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Association study between iron-related genes polymorphisms and Parkinson's disease
C Borie et al.
JOURNAL OF NEUROLOGY (2002)
Dopamine-dependent neurotoxicity of α-synuclein:: A mechanism for selective neurodegeneration in Parkinson disease
J Xu et al.
NATURE MEDICINE (2002)
Tyrosine 125 of α-synuclein plays a critical role for dimerization following nitrative stress
T Takahashi et al.
BRAIN RESEARCH (2002)
Methionine oxidation inhibits fibrillation of human α-synuclein in vitro
VN Uversky et al.
FEBS LETTERS (2002)
Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism
MJ Volles et al.
BIOCHEMISTRY (2002)
Biophysical properties of the synucleins and their propensities to fibrillate -: Inhibition of α-synuclein assembly by β- and γ-synucleins
VN Uversky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine
E Junn et al.
NEUROSCIENCE LETTERS (2002)
Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro
JA Cohlberg et al.
BIOCHEMISTRY (2002)
α-Synuclein is phosphorylated in synucleinopathy lesions
H Fujiwara et al.
NATURE CELL BIOLOGY (2002)
Tubulin seeds α-synuclein fibril formation
MA Alim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice -: Paraquat and α-synuclein
AB Manning-Bog et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review - Report of the quality standards subcommittee of the American Academy of Neurology
JM Miyasaki et al.
NEUROLOGY (2002)
Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form
HJ Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration
BA Citron et al.
NEUROCHEMISTRY INTERNATIONAL (2002)
Parkinsonism in Ontario - Increased mortality compared with controls in a large cohort study
M Guttman et al.
NEUROLOGY (2001)
Multiple phosphorylation of α-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation
A Negro et al.
FASEB JOURNAL (2001)
α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome
GK Tofaris et al.
FEBS LETTERS (2001)
Stabilization of partially folded conformation during α-synuclein oligomerization in both purified and cytosolic preparations
VN Uversky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein -: A possible molecular link between Parkinson's disease and heavy metal exposure
VN Uversky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct
KA Conway et al.
SCIENCE (2001)
β-synuclein inhibits α-synuclein aggregation:: A possible role as an anti-parkinsonian factor
M Hashimoto et al.
NEURON (2001)
Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease
E Rockenstein et al.
BRAIN RESEARCH (2001)
Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein
J Li et al.
BIOCHEMISTRY (2001)
Regulation of the 75-kDa subunit of mitochondrial complex I by iron
E Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Ubiquitination of a new form of α-synuclein by parkin from human brain:: Implications for Parkinson's disease
H Shimura et al.
SCIENCE (2001)
Pesticides directly accelerate the rate of α-synuclein fibril formation:: a possible factor in Parkinson's disease
VN Uversky et al.
FEBS LETTERS (2001)
Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development
KTY Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Conformational properties of α-synuclein in its free and lipid-associated states
D Eliezer et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Evidence for a partially folded intermediate in α-synuclein fibril formation
VN Uversky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
α-synuclein forms a complex with transcription factor Elk-1
A Iwata et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice
T LaVaute et al.
NATURE GENETICS (2001)
Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms
Yu Xia et al.
JOURNAL OF ALZHEIMERS DISEASE (2001)
In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [3H]dihydrorotenone
DJ Talpade et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Combinatorial mRNA regulation: Iron regulatory proteins and iso-iron-responsive elements (Iso-IREs)
EC Theil et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
BI Giasson et al.
SCIENCE (2000)
α-synuclein membrane interactions and lipid specificity
EJ Jo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Interaction of human α-synuclein and Parkinson's disease variants with phospholipids -: Structural analysis using site-directed mutagenesis
RJ Perrin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The early treatment of Parkinson's disease: levodopa, dopamine agonists or both
MB Stern
PARKINSONISM & RELATED DISORDERS (2000)
Synucleins are a novel class of substrates for G protein-coupled receptor kinases
AN Pronin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Sequestration of iron by Lewy bodies in Parkinson's disease
RJ Castellani et al.
ACTA NEUROPATHOLOGICA (2000)
α-synuclein promotes mitochondrial deficit and oxidative stress
LJ Hsu et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Dityrosine cross-linking promotes formation of stable α-synuclein polymers -: Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies
JM Souza et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Metal-catalyzed oxidation of α-synuclein in the presence of copper(II) and hydrogen peroxide
SR Paik et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells
DC Jones et al.
JOURNAL OF NEUROCHEMISTRY (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Membrane association and protein conformation of α-synuclein in intact neurons -: Effect of Parkinson's disease-linked mutations
PJ McLean et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
KA Conway et al.
BIOCHEMISTRY (2000)
α-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP
M Vila et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Inhibition of catechol-O-methyltransferase. Optimizing the dopaminergic therapy with entacapone in Parkinson's disease
G Arnold et al.
NERVENARZT (2000)
Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy
KA Conway et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
NW Kowall et al.
NEUROREPORT (2000)
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
A Abeliovich et al.
NEURON (2000)
Share Paper
